Bendamustine + Rituximab
Bendamustine + Rituximab is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
1
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Clinical Trials (6)
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6